Stepan Approves Share Repurchase Authorization
NORTHFIELD, Ill., Feb. 21, 2013 /PRNewswire/ -- On February 19, 2013, the Board of Directors of Stepan Company authorized the Company to repurchase up to 1,000,000 shares of its outstanding common stock. This repurchase authorization replaces the 1,000,000 share authorization (split adjusted) approved on February 11, 2009, of which the remaining unutilized repurchase authorization of 170,542 shares is cancelled. The Company will repurchase shares from time to time for cash in open market or private transactions in accordance with applicable securities and stock exchange rules. The timing and amount of the repurchases will be determined by the Company's management based on their evaluation of market conditions and share price.
"The share repurchase authorization demonstrates our confidence in Stepan's growth and commitment to promote long-term shareholder value," said F. Quinn Stepan, Jr. , President and Chief Executive Officer.
Stepan Company, headquartered in Northfield, Illinois, is a leading producer of specialty and intermediate chemicals used in household, industrial, personal care, agricultural, food and insulation-related products. The common and preferred stocks are traded on the New York and Chicago Stock Exchanges under the symbol SCL and SCLPR.
SOURCE Stepan Company
More by this Source
Stepan Declares Quarterly Dividend
May 01, 2013, 08:30 ET
Stepan Reports First Quarter Results
Apr 30, 2013, 06:01 ET
Stepan Announces Agreement To Acquire North American Polyester Resins Business From Bayer
Apr 30, 2013, 06:00 ET
Featured Video
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.




